AKT1 and breast carcinoma: AKT inhibitors in clinical trials include ipatasertib (Phase III trials, NCT04650581) [56] and capivasertib, an ATP-competitive pan-Akt inhibitor (in Phase II/III trials [57]), both of which have shown promising results in breast cancer.